ASXL1 and myelodysplastic syndrome: As expected, patients with MDS-R mutations were more frequently stratified into the unfavorable-risk group based on the 2017 ELN risk classification, regardless of a younger or older age status, since ASXL1 and RUNX1 mutations are assigned to the unfavorable-risk category by this classification.